menu

How Will the Game Change with the Entry of New Agents/MOAs/Different Pharmacokinetics for Resistant Hypertension?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Stop the Resistance Associated with Resistant Hypertension – Addressing Quality of Care

How Will the Game Change with the Entry of New Agents/MOAs/Different Pharmacokinetics for Resistant Hypertension?

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program discusses the role of endothelin-receptor antagonists and their unique function and role in the management of resistant hypertension, beyond their known role in the management of pulmonary arterial hypertension. More specifically, the education will focus on the worsened prognosis associated with diagnostic delay, the challenges with current treatment modalities, the lack of guidelines being updated to reflect current clinical practices, and providing the community with a more in-depth and better understanding of the profiles associated with endothelin-receptor antagonists.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team involved in the management of patients with resistant hypertension. This includes, but is not limited to, cardiologists, emergency medicine specialists, hospitalists, nephrologists, neurologists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other clinicians involved in the management of patients with the diagnosis and management of resistant hypertension.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Identify appropriate patients with a diagnosis of resistant hypertension, in the presence of various comorbidities and inequities in healthcare
    2. Apply the latest evidence-based approaches to prevent diagnostic delays and maximize management prognostic outcomes for resistant hypertension
    3. Demonstrate the role of current guidelines and their application to current clinical practice patterns in addressing the management of resistant hypertension
    4. Understand emerging data of classes and mechanisms of drugs, with a focus on adherence, combinations, and compliance of pharmacological treatments in controlling resistant hypertension
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty have reported relationships with ineligible companies:

    George L. Bakris, MD, faculty for this educational event, has received consulting fees from Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, Novo Nordisk, Dia Medica Therapeutics, and InREGEN.

    Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, faculty for this educational event, has received consulting fees from Amgen, Novartis, Medtronic, Eli Lilly, and Quantum Genomics.

    Michael G. Nanna, MD, MHS, faculty for this educational event, has no relevant financial relationships with ineligible companies.

    Sudarshan Rajagopal, MD, PhD, faculty for this educational event, received consulting fees from Altavant, Gossamer Bio, Insmed, Janssen, Liquidia, Polarean, and United Therapeutics; received research funding from Janssen, United Therapeutics, and Altavant; has ownership interest in Apie Therapeutics; receives royalties from Polarean; and is a patent holder with Polarean. 

    Nishant Shah, MD, FACC, faculty for this educational event, has received research funding from Amgen, Novartis, and Janssen; and has received consulting fees from Amgen, Novartis, and Esperion.

    Sreekanth Vemulapalli, MD, faculty for this educational event, received consulting fees from American College of Physicians, Edwards Lifesciences, and Medtronic; received research funding from Cytokinetics, Abbott Vascular, Boston Scientific, American College of Cardiology, Society of Thoracic Surgeons.

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Vin Kalathiveetil, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    Prerna Poojary, PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 8/15/2022 through 8/15/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
Schedule6 Dec 2022